Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis
Status:
Not yet recruiting
Trial end date:
2024-11-23
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label study to evaluate the safety and efficacy of
KER-050 as monotherapy or in combination with ruxolitinib in participants with Myelofibrosis.